Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ART-648 in mild to moderate bullous pemphigoid
jRCT2071210034Phase 2Completed
- Sponsor
- ARTham Therapeutics, Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAK-648 in Bullous Pemphigoid (BP), sponsored by ARTham Therapeutics, Inc. Primary endpoint: Cessation of new lesion formation at week 4. Started Oct 2021; status: completed.
02
Drugs
TAK-648
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2071210034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210034.